These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 35638489)
1. Characteristics and quality of life in pemphigus patients. Tee CT; Lee CS; Gunabalasingam P Med J Malaysia; 2022 May; 77(3):324-330. PubMed ID: 35638489 [TBL] [Abstract][Full Text] [Related]
2. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus. Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP Front Immunol; 2019; 10():2571. PubMed ID: 31781098 [TBL] [Abstract][Full Text] [Related]
3. Beyond the skin: disease parameters in pemphigus. Viti G; Forcella C; Feliciani C; Murrell DF Ital J Dermatol Venerol; 2021 Apr; 156(2):147-150. PubMed ID: 33960750 [TBL] [Abstract][Full Text] [Related]
4. Sexual quality of life in patients with pemphigus: A case-control study. Maione V; Bettolini L; Cozzi C; Bighetti S; Tomasi C; Calzavara-Pinton P J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):761-768. PubMed ID: 38071729 [TBL] [Abstract][Full Text] [Related]
5. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Boulard C; Duvert Lehembre S; Picard-Dahan C; Kern JS; Zambruno G; Feliciani C; Marinovic B; Vabres P; Borradori L; Prost-Squarcioni C; Labeille B; Richard MA; Ingen-Housz-Oro S; Houivet E; Werth VP; Murrell DF; Hertl M; Benichou J; Joly P; Br J Dermatol; 2016 Jul; 175(1):142-9. PubMed ID: 26800395 [TBL] [Abstract][Full Text] [Related]
6. Family impact of pemphigus disease in an Iranian population using the Family Dermatology Life Quality Index. Ghodsi SZ; Asadi A; Ghandi N; Balighi K; Mahmoudi H; Abedini R; Ghiasi M; Lajevardi V; Chams-Davatchi C; Daneshpazhooh M Int J Womens Dermatol; 2020 Dec; 6(5):409-413. PubMed ID: 33898709 [TBL] [Abstract][Full Text] [Related]
7. Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies. Mohebi F; Tavakolpour S; Teimourpour A; Toosi R; Mahmoudi H; Balighi K; Ghandi N; Ghiasi M; Nourmohammadpour P; Lajevardi V; Abedini R; Azizpour A; Nasimi M; Daneshpazhooh M BMC Dermatol; 2020 Oct; 20(1):13. PubMed ID: 33129291 [TBL] [Abstract][Full Text] [Related]
8. Establishing minimal clinically important differences for the Pemphigus Disease Area Index. Tseng H; Stone C; Shulruf B; Murrell DF Br J Dermatol; 2024 Oct; 191(5):823-831. PubMed ID: 39001612 [TBL] [Abstract][Full Text] [Related]
9. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444 [TBL] [Abstract][Full Text] [Related]
10. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086 [TBL] [Abstract][Full Text] [Related]
11. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Rencz F; Gulácsi L; Péntek M; Szegedi A; Remenyik É; Bata-Csörgő Z; Bali G; Hidvégi B; Tamási B; Poór AK; Hajdu K; Holló P; Kinyó Á; Sárdy M; Brodszky V Br J Dermatol; 2020 May; 182(5):1167-1175. PubMed ID: 31419310 [TBL] [Abstract][Full Text] [Related]
12. Psoriasis affects patient's quality of life more seriously in female than in male in Japan. Mabuchi T; Yamaoka H; Kojima T; Ikoma N; Akasaka E; Ozawa A Tokai J Exp Clin Med; 2012 Sep; 37(3):84-8. PubMed ID: 23032250 [TBL] [Abstract][Full Text] [Related]
13. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. Paradisi A; Sampogna F; Di Pietro C; Cianchini G; Didona B; Ferri R; Abeni D; Tabolli S J Am Acad Dermatol; 2009 Feb; 60(2):261-9. PubMed ID: 19004524 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. Saleh MA; Zaraa I; Doss N; Saleh NA; Murrell DF An Bras Dermatol; 2019; 94(4):399-404. PubMed ID: 31644610 [TBL] [Abstract][Full Text] [Related]
15. Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. Tamási B; Brodszky V; Péntek M; Gulácsi L; Hajdu K; Sárdy M; Szegedi A; Bata-Csörgő Z; Kinyó Á; Rencz F Br J Dermatol; 2019 Apr; 180(4):802-809. PubMed ID: 29897626 [TBL] [Abstract][Full Text] [Related]
16. Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. Ghodsi SZ; Chams-Davatchi C; Daneshpazhooh M; Valikhani M; Esmaili N J Dermatol; 2012 Feb; 39(2):141-4. PubMed ID: 21967321 [TBL] [Abstract][Full Text] [Related]
17. Quality of Life Assessment in Korean Patients with Pemphigus. Sung JY; Roh MR; Kim SC Ann Dermatol; 2015 Oct; 27(5):492-8. PubMed ID: 26512162 [TBL] [Abstract][Full Text] [Related]
18. The effect of autoimmune blistering diseases on work productivity. Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897 [TBL] [Abstract][Full Text] [Related]
20. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study. Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]